The exploitation of Hepatitis C virus-like particles vaccine against genotype 4 by bioinformatics | ||
| International Journal of Health Sciences (Egypt) | ||
| Article 1, Volume 1, Issue 3, October 2023, Pages 75-83 PDF (649.92 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ijhegy.2023.202614.1016 | ||
| Author | ||
| Mohammed M Kassab* | ||
| Instructor of microbiology,immunology,faculty of pharmacy,Cairo university,Egypt Specialist of pharmacology, toxicology and clinical pharmacy. | ||
| Abstract | ||
| Aim: To counteract Hepatitis C viral lethality, an insect recombinant DNA vaccine of Hepatitis C virus genotype 4 subtype 4a was developed using E1, E2, and Capsid protein structural proteins. Methodology: In the current study, HCV-like particles vaccinations composed of coherent structural proteins (E1, E2, and Capsid protein) of HCV were created in an expression host insect cell line employing a Baculovirus expression vector. Recombinant Baculovirus VLPs were produced by modified bac-to-bac site-specific transposition and purified via affinity chromatography. The current vaccine's immunogenicity was assessed in preclinical animal testing on transgenic mice, followed by clinical trials stages 1/2. Results: The current vaccine achieved 71% efficacy in animal models and 63% efficacy throughout stages 1-2 of human clinical trials. They have little biological influence and have few negative implications. The effect lingered for a time. An HCV-like particle immunization improved both humoral and cell-mediated protection against hepatitis C virus infection. Advantages: It is not feasible to revert to virulence.Cons: Because the vaccine virus cannot be expelled or transferred to people who have not received the immunization, it does not contribute to herd immunity against this viral infection. Conclusions: The immunization proved effective in avoiding HCV virus infection in the current study. To counteract the HCV virus's rapid mutation rate, it must be updated on a frequent basis. | ||
| Keywords | ||
| Hepatitis C virus; Vaccine; Bio-informatics | ||
|
Statistics Article View: 193 PDF Download: 171 |
||